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Abstract 
FH22 has been previously identified as a calcium-binding protein from the common liver fluke, 
Fasciola hepatica. It is part of a family of at least four proteins in this organism which combine an EF-
hand containing N-terminal domain with a C-terminal dynein light chain-like domain.  Here we report 
further biochemical properties of FH22, which we propose should be renamed FhCaBP1 for 
consistency with other family members.  Molecular modelling predicted that the two domains are 
linked by a flexible region and that the second EF-hand in the N-terminal domain is most likely the 
calcium ion binding site.  Native gel electrophoresis demonstrated that the protein binds both 
calcium and manganese ions, but not cadmium, magnesium, strontium, barium, cobalt, copper(II), 
iron (II), nickel, zinc, lead or potassium ions.  Calcium ion binding alters the conformation of the 
protein and increases its stability towards thermal denaturation.  FhCaBP1 is a dimer in solution and 
calcium ions have no detectable effect on the protein’s ability to dimerise.  FhCaBP1 binds to the 
calmodulin antagonists trifluoperazine and chlorpromazine.  Overall, the FhCaBP1’s biochemical 
properties are most similar to FhCaBP2 a fact consistent with the close sequence and predicted 
structural similarity between the two proteins. 
 
Keywords:  Neglected tropical disease; EF-hand; dynein light chain; calcium binding; liver fluke; 
trematode protein 
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Introduction 
The common liver fluke, Fasciola hepatica expresses at least four members of a family of unusual 
calcium binding proteins (Russell and Timson, 2014).  These proteins combine an N-terminal EF-hand 
domain and a C-terminal dynein light chain-like (DLC-like) domain.  Similar proteins are found in 
other species from the phylum Platyhelminthes (Thomas and Timson, 2016).  The best characterised 
of these are the tegumental allergen like (TAL) proteins from Schistosoma mansoni (Fitzsimmons, et 
al., 2012, Francis and Bickle, 1992, Hoffmann and Strand, 1997, Jeffs, et al., 1991, Mohamed, et al., 
1998, Santiago, et al., 1998).  This species expresses 13 family members, some of which have been 
shown to elicit IgE-mediated immune responses in the host (Fitzsimmons, et al., 2012, Fitzsimmons, 
et al., 2007, Webster, et al., 1997).  Proteins from this family have also been identified and 
characterised from other species in the genus Schistosoma, from the Chinese liver fluke Clonorchis 
sinensis (Huang, et al., 2007, Kim, et al., 2012, Senawong, et al., 2012, Subpipattana, et al., 2012, 
Vichasri-Grams, et al., 2006), the giant liver fluke Fasciola gigantica and the carcinogenic liver fluke, 
Opisthorchis viverrini (Fitzsimmons, et al., 2004, Li, et al., 2000, Santiago, et al., 1998, Waine, et al., 
1994, Xu, et al., 2014, Zhang, et al., 2012). 
 
While many of the proteins have been localised to the tegument of the worm, their in vivo functions 
have not been elucidated (Fitzsimmons, et al., 2012, Havercroft, et al., 1990, Huang, et al., 2007, Kim, 
et al., 2012, Lopes, et al., 2009, Mohamed, et al., 1998, Subpipattana, et al., 2012, Xu, et al., 2014, 
Zhang, et al., 2012).  From the available data it is evident that, despite clear sequence similarities, 
differences exist between the proteins at the biochemical level.  For example, while the EF-hand 
domain is a well-characterised calcium ion binding structure, at least one S. mansoni TAL protein 
(SmTAL3; Sm20.8; UniProt:  P91804) does not bind calcium (Mohamed, et al., 1998, Thomas, et al., 
2015).  In F. hepatica the four proteins from this family are FH22 (Uniprot:  O46121), FhCaBP2 
(A0A0B5GUS3), FhCaBP3 (K7WKP9) and FhCaBP4 (I6U578).  Of these, FH22 was discovered almost 
two decades ago and shown to interact with calcium ions.  Since then, no further work has been 
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reported on this protein (Ruiz de Eguino, et al., 1999).  FhCaBP2 binds calcium and manganese ions 
through the second EF-hand motif in the N-terminal domain.  It forms a homodimer and calcium ion 
binding has no effect on dimer formation (Nguyen, et al., 2016, Thomas and Timson, 2015).  FhCaBP3 
also interacts with calcium and manganese ions (Banford, et al., 2013).  However in this case, calcium 
ion binding promotes the monomeric over the dimeric state (which is favoured in the absence of 
these ions).  Interestingly, in FhCaBP4 the situation is reversed:  calcium ion binding promotes 
dimerization (Orr, et al., 2012).  All three of these proteins interact with calmodulin antagonists and 
related drugs; however, the range of drugs which binds varies between the proteins, demonstrating 
that they can be distinguished pharmacologically (Banford, et al., 2013, Orr, et al., 2012, Thomas and 
Timson, 2015, Thomas and Timson, 2016). 
 
Despite uncertainties about the role of these proteins, their tegumental location and widespread 
importance of calcium signalling in eukaryotes suggests that these proteins may have potential as 
drug or vaccine targets.  The increasingly widespread resistance to the drug of choice for treating 
Fasciola spp. infections (triclabendazole) underlies the urgent need to explore a diverse range of 
potential, novel targets for future drug discovery (Brennan, et al., 2007, Cabada, et al., 2016, Gil, et 
al., 2014, Winkelhagen, et al., 2012).  A key initial step in this process is the biochemical 
characterisation of the protein concerned, which was the aim of the work presented in this paper.  
We present the biochemical characterisation of FH22 (including predicted three-dimensional 
structure, ion binding, oligomerisation properties and interactions with calmodulin antagonists), 
building on previously reported work on this protein and complementing our own work on other 
family members (Ruiz de Eguino, et al., 1999)(Banford, et al., 2013, Nguyen, et al., 2016, Orr, et al., 
2012, Thomas and Timson, 2015).  We report data on the protein’s ion and drug binding properties, 
predicted structure and dimerization.  For consistency with other family members (and the 
conventions applied in F. gigantica), we propose that FH22 should be renamed FhCaBP1. 
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Materials and Methods 
Bioinformatics and molecular modelling 
Physical properties of the protein were estimated using ProtParam as implemented in ExPASY 
(Gasteiger, et al., 2005).  An initial molecular model was generated using Phyre2 (Krieger, et al., 
2009), followed by solvation and energy minimisation by YASARA (Kelley, et al., 2015).  To generate a 
model of the protein with a calcium ion bound at the second EF-hand the initial model was aligned 
using PyMol (www.pymol.org) to the highest ranked template (as judged by Phyre2) with a bound 
calcium ion (the mouse Reps1 EH domain; PDB:  1FI6 (Kim, et al., 2001)).  This calcium-bound 
structure was then minimised using YASARA.  As an independent check, 3DLigandSite was used to 
predict likely binding ligands in the apo-FhCaBP1 model (Wass, et al., 2010).  The apo- and calcium 
bound FhCaBP1 structures are available as supplementary data to this paper. 
 
Expression and purification of FhCaBP1 
The sequence encoding FhCaBP1 was amplified from F. hepatica cDNA by PCR using primers 
designed to facilitate insertion into pET43 Ek/LIC (Merck, Nottingham, UK) using ligation independent 
cloning and following the manufacturer’s protocol.  This vector inserts sequence encoding the amino 
acids MAHHHHHHVDDDDK at the 5’ end of the coding sequence, thus facilitating purification by 
metal affinity resins.  The insert sequence was verified (GATC Biotech, London, UK). 
 
The expression vector was transformed into Escherichia coli HMS174(DE3) and a single colony 
resulting from this transformation used to inoculate a culture (5ml, Luria-Bertani medium 
supplemented with 100 µgml-1 ampicillin) which was grown, shaking overnight, at 37 °C.  This culture 
was diluted into 1 l of the same medium and grown until mid-log phase (i.e. when A600=0.6-0.8, 
typically 3-4 h).  The culture was then induced with IPTG (1.3 mM), grown for a further 3 h and 
harvested by centrifugation at 4200 g for 15 min.  The supernatant was discarded, the pellets 
resuspended in approximately 20 ml of buffer R (50 mM Hepes-OH, pH 7.5, 150 mM NaCl, 10% (v/v) 
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glycerol) and the suspensions frozen at -80 °C until required. 
 
The cell suspensions were thawed and disrupted by sonication on ice (three pulses of 100 W each 
lasting 30 s with 30-60 s gaps in between for cooling).  Debris was removed by centrifugation (22,000 
g for 20 min).  The supernatant was immediately applied to a cobalt agarose column (His-Select, 
Sigma, 1 ml) which had been pre-equilibrated in buffer A (50 mM Hepes-OH, pH 7.5, 500 mM NaCl, 
10% (v/v) glycerol).  The supernatant was allowed to pass through under gravity and the column was 
then washed with 20 ml of buffer A.  FhCaBP1 was then eluted using buffer B (three time 2 ml 
aliquots of buffer A supplemented with 250 mM imidazole).  SDS-PAGE was used to identify the 
protein-containing fractions and monitor purity.  FhCaBP1 was dialysed overnight at 4 °C against 
buffer R supplemented with 1 mM DTT, then divided into aliquots (50-100 µl) and frozen at -80 °C. 
 
Native gel electrophoresis 
FhCaBP1 (10 µM) was resolved by discontinuous electrophoresis (Ornstein and Davis, 1964).  Protein 
samples (total reaction volume was 10 µl) were incubated for 30 min at 20 °C in the presence of 
either EGTA (1 mM) or EGTA (1 mM)/metal salt (2 mM).  An equal volume of non-denaturing gel 
loading buffer (120 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 0.005% (w/v) bromophenol blue, 1% 
(w/v) DTT) was then added and the samples resolved on 15% polyacrylamide gels (running buffer:  
25 mM Tris-HCl, pH 8.3, 250 mM glycine) at 20 mA (constant current) until the bromophenol blue ran 
off the end of the gel (typically 45-60 min).  Gels were then stained in 0.25%(w/v)Coomassie 
blue/10% (v/v) acetic acid/45% (v/v) ethanol overnight and destained in 0.75%(v/v) acetic 
acid/0.5%(v/v) ethanol. 
 
Analytical methods 
Protein-protein cross-linking was carried out using glutaraldehyde in a total reaction volume of 9 µl 
with 20 mM Hepes-OH, pH 7.4 as the buffer.  FhCaBP1 (20 µM) was incubated at 37 °C for 60 min in 
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the presence of either 2 mM EGTA or 2 mM EGTA/4 mM calcium chloride.  Glutaraldehyde (0.1-
0.3%(v/v)) was then added and the reaction was allowed to proceed for 5 min before being 
terminated by the addition of Tris-HCl, pH 8.0 (1µl of 1 M solution) followed by 9 µl of SDS-PAGE 
loading buffer (as native gel loading buffer plus 4%(v/v) SDS) and heating at 95 °C for 3 min.  
Reactions were analysed by 15% SDS-PAGE. 
 
Fluorescence spectra were collected using a Spectra Max Gemini XS fluorescence plate reader and 
SOFTmax PRO software.  Samples (total volume 120 µl) were loaded in triplicate into black 96-well 
plates and contained 15 µM FhCaBP1 and either 1 mM EGTA or 1 mM EGTA/2 mM calcium chloride.  
These samples were incubated at 37 °C for 75 min before reading; excitation was at 280 nm and 
emission monitored over the range 310-410 nm. 
 
Differential scanning fluorimetry (DSF) was carried out using a Rotor-Gene Q quantitative PCR 
machine and software as previously described (Thomas, et al., 2015, Thomas and Timson, 2015).  
Samples (total volume 20 µl with 10 mM Hepes-OH, pH 7.4) contained FhCaBP1 (15 µM) and SYPRO 
Orange (10×; manufacturer’s concentration definition) and drugs or divalent ions as required. 
 
Protein concentrations were estimated using the method of Bradford with BSA as a standard 
(Bradford, 1976). 
 
Results 
Expression and purification of FhCaBP1 
Sequencing of the insert generated by PCR revealed three coding differences to the FH22 sequence 
deposited in the databases (CAA06036).  These are at positions 85 and 86 where the residues are 
Pro-Pro in CAA06036, but Arg-Ala in our sequence and at position 180 (Tyr in CAA06036 and His in 
our sequence).  Interestingly these changes are identical to the residues seen at the same positions 
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in the orthologous protein from F. gigantica (FgCaBP1; UniProt:  Q45TR6; GenBank:  AAZ20312).  
However, this protein differs from FhCaBP1 at four other positions, suggesting that the differences 
we observed are not the result of contamination.  The new sequence has been submitted to 
GenBank with the accession code KU647725.  FhCaBP1 can be expressed in, and purified from, E. coli 
(Fig. 1).  The protein was produced in good yield (typically 4 mg per litre of bacterial culture). 
 
FhCaBP1 is similar in sequence and structure to FhCaBP2 
The most similar known protein to FhCaBP1 is FgCaBP1 (AAZ20312; 186/190 identical residues) and 
the most similar F. hepatica protein is FhCaBP2 (AJF23779; 147/187 identical residues).  FhCaBP1 has 
a predicted molecular mass of 22.0 kDa and a computationally estimated pI of 5.55. 
 
Prediction of the three-dimensional structure of FhCaBP1 revealed a two domain protein joined by a 
linker (Fig. 2a).  This is similar to the predicted structures of the other FhCaBP and SmTAL family 
members (Banford, et al., 2013, Orr, et al., 2012, Thomas, et al., 2015, Thomas and Timson, 2015).  In 
common with the other family members, the region linking the two domains is expected to be 
flexible, allowing the two domains to alter their relative orientation.  Two of the three residues (Arg-
85, Ala-86) which differ between our sequence and the previously published one lie at the beginning 
of this linker.  If the linker is flexible, it may be more tolerant of amino acid changes than other parts 
of the protein. 
 
Alignment of the apo-FhCaBP1 structure to the highest ranked template with calcium bound, 
suggested that the ion binds to the second EF-hand in the N-terminus.  This is consistent with what 
was observed in FhCaBP2 where site-directed mutagenesis of a key glutamate residue in this EF-hand 
abolished calcium binding activity (Thomas and Timson, 2015).  That a calcium ion binds at this site 
was also supported by predictions from 3DLigandSite (data not shown).  This predicted calcium ion 
binding to the second EF-hand based on data from 21 different crystal structures.  Therefore, a 
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calcium-bound structure was generated with the ion bound at the second EF-hand (Fig. 2a).  Calcium 
ion binding was not predicted to result in major structural changes; the apo and calcium-bound 
structures aligned with a root mean square deviation (rmsd) of 0.433 Å over 2642 equivalent atoms.  
Comparison of energy-minimised models based on the primary sequence reported here and the 
sequence previously submitted to the database also showed no major predicted structural 
differences (rmsd 0.400 Å over 2466 equivalent atoms). 
 
EF-hands provide coordination for the bound ions using both main chain and backbone functional 
groups.  These are arranged approximately at right angles and are known at the X, Y, Z, -X, -Y and –Z 
positions.  Bioinformatics studies have established the consensus residues at these positions which 
are consistent with calcium ion binding (Gifford, et al., 2007).  In the first EF-hand in FhCaBP1, the 
sequence deviates from the consensus only at the –Y position (Ala-27) (Fig. 2b).  The preferred 
residue here is threonine (Gifford, et al., 2007).  However, since it is the backbone carbonyl group 
which coordinates the ion at this position, considerable deviation from the consensus is possible.  
Despite this, it appears that this site is non-functional.  The second EF-hand conforms to the 
consensus at all positions except -Y (Lys-61, Fig. 2c).  Despite the introduction of a positive charge in 
the side chain, this has been shown to be consistent with calcium and manganese ion binding at this 
site (Sanchez-Barrena, et al., 2005, Thomas and Timson, 2015).  Interestingly all members of the 
FhCaBP family characterised to date have a lysine at this position in the second EF-hand.  The 
functional significance of this, if any, is not yet clear. 
 
FhCaBP1 binds calcium and manganese ions 
Native gel electrophoresis showed that addition of EGTA (a calcium-specific chelating agent) to 
FhCaBP1 caused the protein to have increased mobility in native PAGE.  Addition of a molar excess of 
calcium ions to the FhCaBP1/EGTA mixture resulted in a similar electrophoretic mobility to the wild-
type protein (Figure 3a).  This suggests that the purified, recombinant protein is largely isolated in a 
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calcium-bound form.  EGTA removes these calcium ions, but adding exogenous calcium ions in molar 
excess over the EGTA results in a calcium-bound form of the protein.  The ability of the protein to 
bind a range of other ions was tested (each in the presence of EGTA to remove any calcium ions 
bound to the purified protein).  Of these ions, only manganese caused a reduction in mobility similar 
to calcium (Figure 3a).  Thus, like other CaBP family members, FhCaBP1 can interact with this ion in 
addition to calcium.  FhCaBP3 and FhCaBP4 both bind other ions in addition to calcium and 
manganese; however, like FhCaBP1, FhCaBP2 only binds these two ions (Banford, et al., 2013, Orr, et 
al., 2012, Thomas and Timson, 2015).  FhCaBP1’s ability to bind calcium ions was confirmed by 
intrinsic fluorescence measurements and differential scanning fluorimetry.  The intrinsic fluorescence 
of FhCaBP1 was quenched in the presence of 2 mM calcium chloride/1 mM EGTA compared to 
treatment with 1 mM EGTA (Figure 3b).  This suggests that calcium ions bind to the protein resulting 
in conformational changes which affect the environment of tryptophan residues.  In the presence of 
1 mM calcium chloride/0.5 mM EGTA the melting temperature (Tm) of FhCaBP1 was 69.2±0.6 °C 
compared to 67.5±0.0 °C in the presence of 0.5 mM EGTA (Figure 3c).  This suggests that calcium ions 
bind to FhCaBP1, stabilising the protein and make it more resistant to thermal denaturation. 
 
FhCaBP1 dimerises in a calcium-independent manner 
Addition of glutaraldehyde to FhCaBP1 resulted in the appearance of an additional band when the 
reaction was analysed by SDS-PAGE (Fig. 4).  This band corresponds to a molecular mass of 45 kDa, 
i.e. approximately twice the mass of the monomeric protein.  In contrast to FhCaBP3 and FhCaBP4, 
but similar to FhCaBP2, the presence of calcium ions did not markedly affect the crosslinking.  Similar 
results were obtained when bissulfosuccinimidyl suberate (BS3) was used as a crosslinker 
(Supplementary Figure S1).  Therefore, FhCaBP1 forms dimers which are not affected by the calcium 
ion concentration. 
 
FhCaBP1 binds some calmodulin antagonists 
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DSF revealed that the calmodulin antagonists trifluoperazine (TFP) and chlorpromazine (CPZ) cause a 
reduction in the overall thermal stability of FhCaBP1 (Table 1; Supplementary Figure S2).  In contrast, 
praziquantel (PZQ), N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W7) and 
thiamylal had no significant effect on the Tm of FhCaBP1.  The most likely explanation is that TFP and 
CPZ bind to a partially folded form of the protein thus shifting the equilibrium between folded and 
partially folded protein away from the folded form, resulting in an overall destabilisation and lower 
Tm value.  These results are similar to those seen in FhCaBP2, which is also destabilised by TFP and 
CPZ (Thomas and Timson, 2015). 
 
Discussion 
Overall, FhCaBP1 shows greatest similarity in its biochemical properties to FhCaBP2.  Notably both 
bind both calcium and manganese ions (but failed to interact with any of the other ions tested) and 
both dimerise in a calcium independent manner.  Given the overall sequence and predicted 
structural similarity, it is likely that other experimental findings about FhCaBP2 will also hold for 
FhCaBP2.  Therefore, we predict that the second EF-hand in the N-terminal domain is most likely 
they key calcium ion binding site in FhCaBP1; this prediction is also consistent with the molecular 
modelling presented in this paper.  The close sequence, structural and functional similarities 
between these two proteins suggests that they may have arisen from a relatively recent gene 
duplication event and it seems likely that there will be some functional overlap between the two 
proteins in vivo.  It remains to be determined how extensive this overlap is.  Indeed the physiological 
roles of this protein family remain elusive.  However, it is reasonable to speculate that one function 
may be to link calcium signalling and dynein-mediated processes. 
 
In order to function as a signalling protein, calcium binding must result in some change to the 
protein, which can be sensed by other cellular systems.  Here we detected changes to the 
electrophoretic mobility, tryptophan fluorescence and thermal stability as a consequence of calcium 
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ion binding.  All these indicate some form of conformational change in the protein resulting from ion 
binding.  However, molecular modelling did not predict substantial changes to the overall fold and so 
it is likely that these changes largely affect the arrangement of loops and the conformation amino 
acid side chains on the surface of the protein.  The linker between the domains is likely to be highly 
flexible, but the modelling techniques employed here are unlikely to predict accurately changes in 
this region.  Ideally, experimental structures of the full-length protein in the presence and absence of 
bound calcium ions would be available to facilitate more detailed molecular dynamics studies.  To 
date, only two experimental structures of proteins from this family have been determined and both 
are only of the C-terminal DLC-like domain (Costa, et al., 2014, Nguyen, et al., 2016).  Interestingly, in 
both cases, the initial protein in the crystallisation mixes was the full-length one which degraded to 
the DLC-like domain.  It has been suggested that this susceptibility to degradation may be an 
important feature of the in vivo function of the protein (Nguyen, et al., 2016).  The crystal structure 
of the DLC-like domain of FhCaBP2 confirmed biochemical studies that this domain is a dimer 
(Nguyen, et al., 2016, Thomas and Timson, 2015).  The EF-hand domain of this protein also dimerises 
(Thomas and Timson, 2015).  It is likely that the same is true for FhCaBP1.  The importance of 
dimerization to the functioning of these proteins is currently unknown.  It is also interesting to 
speculate that heterodimers of FhCaBP family members may also be found in vivo.  If these do occur 
they would add another potential layer of complexity to FhCaBP-mediated signalling. 
 
By analogy with calmodulin, it is likely that changes to the surface characteristics of FhCaBP1, alter its 
affinity for other proteins thus facilitating its signalling role.  Identification of these binding partners 
is a priority for future research.  The availability of recombinant FhCaBP1 should facilitate 
experiments such as pull-downs, affinity chromatography and co-immunoprecipitation.  The recent 
publication of the draft F. hepatica genome (Cwiklinski, et al., 2015) will facilitate the interpretation 
of molecular genetic approaches (for example two-hybrid screening) to the discovery of binding 
partners.  Selective knock-down of the mRNA coding for FhCaBP1 (and consequent reduction in the 
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amount of protein produced) may enable studies of the effects of reduced concentrations of the 
protein in vivo.  Such experiments would need to be designed carefully to ensure that only FhCaBP1 
(and not other family members) were knocked-down and it would also be necessary to consider 
what phenotypic outputs would be measured.  A recent study on RNAi knock-down of calmodulin-
like proteins in F. hepatica demonstrates that it is possible to target highly similar sequences and 
observe consequent phenotypes (McCammick, et al., 2016).  Once binding partners have been 
identified, it will be necessary to study the downstream signalling processes which are mediated by 
FhCaBP1.  To do this it should be possible to use many of the methods used to study signalling 
pathways in higher eukaryotes.  However, the current lack of reliable cell culture systems for F. 
hepatica will be a significant barrier in doing so. 
 
The likely role of FhCaBP1 (and other members of the family) in calcium-mediated signalling makes 
this protein an interesting potential drug target.  Calmodulin is a target of a number of drugs used in 
the treatment of schizophrenia and other psychiatric conditions (Levin and Weiss, 1977, Marques, et 
al., 2004, Marshak, et al., 1985).  It has also been investigated as a possible anti-cancer drug target 
(Hait, 1987).  This suggests that targeting calcium-binding proteins is pharmacologically viable.  The 
S. mansoni protein SmTAL1 (which has a similar domain structure to FhCaBP1) interacts with the 
highly effective antischistosomal drug praziquantel providing tantalising evidence that the drug’s 
mechanism may involve antagonism of this protein’s signalling actions (Thomas, et al., 2015).  
However, praziquantel is not considered to be active against F. hepatica and there was no evidence 
for interaction between this drug and FhCaBP1 in our studies.  Trifluoperazine and chlorpromazine 
do interact with FhCaBP1 and TFP has been shown to disrupt calmodulin signalling and reduce 
viability in S. mansoni (Thompson, et al., 1986).  However, they are unlikely to be effective drugs for 
the treatment of liver fluke infections:  their actions on brain are likely to result in severe side effects.  
Therefore, if FhCaBP1 was to be targeted, a drug discovery programme would be required.  It is 
possible that TFP and CPZ may be useful lead molecules for medicinal chemistry optimisation aimed 
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at increasing the selectivity for FhCaBP1 over host calmodulin (and other calcium binding proteins).  
The similar structural and biochemical properties of FhCaBP1 and FhCaBP2 suggest that any drug 
designed to antagonise FhCaBP1 would, most likely, also affect the action of FhCaBP2.  This is unlikely 
to result in problems:  indeed hitting two targets rather than one may be beneficial in providing 
effective therapy. 
 
Conclusions 
Structurally and biochemically, FhCaBP1 is most similar to FhCaBP2.  It interacts with calcium and 
manganese ions and forms homodimers.  Dimerisation appears to be unaffected by the presence or 
absence of divalent cations.  The protein interacts with some calmodulin antagonists suggesting that 
it may be possible to identify other small molecules which bind to it with higher selectivity and 
affinity.  Further work is required to identify FhCaBP1’s in vivo roles and the extent of overlap 
between these roles and those of other members of the same protein family in F. hepatica. 
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Figure legends 
Figure 1:  Expression and purification of FhCaBP1.  SDS-PAGE (15%) showing the expression and 
purification of FhCaBP1 (indicated with an arrow to the right of the gel).  M, molecular mass markers 
with masses shown to the left of the gel in kDa; U, total bacterial cell protein extract prior to 
induction with IPTG; I, total bacterial cell protein 3 h after induction; S, proteins released on 
sonication; W1, proteins flowing through the column on the first wash; W2, proteins flowing through 
the column on the second wash; E1, proteins released from the column on the first elution with 
imidazole; E2, proteins released from the column on the second elution with imidazole. 
 
Figure 2:  Predicted structure of FhCaBP1.  (a) The overall predicted fold of the protein with a 
calcium ion bound at the second EF-hand in the N-terminal domain.  The N- and C-termini are 
indicated.  (b) The first EF-hand showing potential ion coordinating residues.  (c) The first EF-hand 
showing predicted ion coordinating residues. 
 
Figure 3:  FhCaBP1 binds calcium and manganese ions.  (a) Native gel electrophoresis of FhCaBP1 
(10 µM) in the presence of various metal ions (for electrophoresis conditions, see Materials and 
Methods).  All samples except U (untreated) contained 1 mM EGTA.  Where present, ions were 2 
mM.  (b) Intrinsic fluorescence spectra of FhCaBP1 (15 µM) in the presence of 1 mM EGTA (dotted 
line) or 1 mM EGTA/2 mM calcium chloride (solid line).  (c) First derivative curves of the Sypro orange 
fluorescence as a function of temperature for FhCaBP1 (15 µM) in the presence of 0.5 mM EGTA 
(dotted line) or 0.5 mM EGTA/1 mM calcium chloride (solid line). 
 
Figure 4:  FhCaBP1 is a dimeric protein.  FhCaBP1 (20 µM) forms dimers (and some higher order 
oligomers), as detected by cross-linking with glutaraldehyde (concentrations shown above the gel).  
Reaction products were resolved on 15% SDS-PAGE and dimers were detected in the presence of 2 
mM EGTA (EGTA) and 2 mM EGTA/4 mM calcium chloride (CaCl2).  M, molecular mass markers (sizes 
16 
 
shown to the left of the gel in kDa); U, untreated protein. 
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Table 1:  The effects of selected drugs on the thermal stability of FhCaBP1 (10 µM) in the presence of calcium chloride (1 mM) and drugs (250 µM) as 
indicated.  Values shown are the mean Tm ± standard deviation (n=3). 
 No drug DMSO PZQ CPZ W7 TFP Thiamylal 
Mean Tm (⁰C) 71.9 ± 0.17 71.77± 0.25 71.57± 0.12 71.2± 0.17 71.6± 0.17 70.8± 0.0 71.9± 0.17 
Mean ΔTm (⁰C) +0.13
ns
 n/a -0.2
ns
 -0.57* -0.17
ns
 -0.97**** +0.13
ns
 
       
Statistical significance determined by comparison to the 1% (v/v) DMSO-treated protein using one-way ANOVA with Tukey’s post hoc test for multiple 
comparisons: ns, not significant (p > 0.05); * p ≤ 0.05; **** P ≤ 0.0001. 
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